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Abstract 
DNA vaccination holds the potential to treat or prevent nearly any immunogenic disease, 
including cancer. To date, these vaccines have demonstrated limited immunogenicity in vivo 
due to the absence of a suitable delivery system which can protect DNA from degradation 
and improve transfection efficiencies in vivo. Recently, microneedles have been described as 
a novel physical delivery technology to enhance DNA vaccine immunogenicity. Of these 
devices, dissolvable microneedles promise a safe, pain-free delivery system which may 
simultaneously improve DNA stability within a solid matrix and increase DNA delivery 
compared to solid arrays. However, to date little work has directly compared the suitability of 
different dissolvable matrices for formulation of DNA-loaded microneedles. Therefore, the 
current study examined the ability of four polymers to formulate mechanically robust, 
functional DNA loaded dissolvable microneedles. Additionally, complexation of DNA to a 
cationic delivery peptide, RALA, prior to incorporation into the dissolvable matrix was 
explored as a means to improve transfection efficacies following release from the polymer 
matrix. Our data demonstrates that DNA is degraded following incorporation into PVP, but 
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not PVA matrices. The complexation of DNA to RALA prior to incorporation into polymers 
resulted in higher recovery from dissolvable matrices, and increased transfection efficiencies 
in vitro. Additionally, RALA/DNA nanoparticles released from dissolvable PVA matrices 
demonstrated 2 - 10 fold higher transfection efficiencies than the corresponding complexes 
released from PVP matrices, indicating that PVA is a superior polymer for this microneedle 
application. 
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1. Introduction 
DNA vaccines have been demonstrated to induce highly specific and potent humoural and 
cellular immune responses against pathogens and antigen-expressing tumours [1], [2]. In 
addition, increased stability, ease of production and no risk of reversion to virulence have 
made DNA vaccines an attractive alternative to their conventional counterparts [1]. Despite 
their potential, DNA vaccines have suffered from limited immunogenicity, owing to a lack of 
suitable delivery system capable of overcoming the barriers to gene delivery. DNA vaccines 
rely on the delivery of antigen-coding DNA to the nucleus of cells, but due to the large 
molecular weight, anionic charge and susceptibility of DNA to enzymatic degradation 
physical injection of DNA often results in very low transfection efficacies [3]. Physical 
methods of disrupting the cell membrane such as electroporation [4] and ballistic delivery [5] 
have been demonstrated to enhance gene expression levels significantly in vivo. However 
these devices are associated with pain,[6], [7] and require the use of expensive specialist 
equipment, making them less acceptable to patients and unsuitable for mass vaccination. 
Alternatively, complexation of DNA with cationic lipids, polymers and peptides [8], [9] 
improves transfection efficacies in vivo via condensation of DNA into the nanoparticle range, 
improving cell uptake. While effective, these vectors have been limited by significant toxicity 
problems [10].  
One strategy to enhance DNA vaccine potency is to deliver DNA into the highly 
immunogenic layers of the skin which harbours a wealth of antigen-presenting cells (APCs) 
[11]. One of the predominant functions of the skin is the exclusion and detection of pathogens 
[12], and  the skin harbours a wealth of epidermal (known as Langherans cells [LCs]) and 
dermal dendritic cells (DCs) which serve as a link between the innate and adaptive branches 
of immunity [13]–[15]. Compared to other “professional” APCs such as macrophages and B 
cells, DCs are especially equipped for T cell activation, owing to the high quantity of co-
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stimulatory ligands at the DC surface which bind to co-stimulatory receptors proximal to the 
T Cell Receptor and thus are prime targets for DNA vaccination [16], [17]. To this end 
microneedles are being investigated as a gene delivery tool [18]. Microneedles can be defined 
as a series of sharp microprojections, ranging up to 1000 µm in length, which are capable of 
piercing the outer barrier of the skin, the stratum corneum (SC), to create transient pores to 
the viable epidermal and dermal layers [19]. Microneedle-mediated DNA vaccines have 
demonstrated efficacy in mouse models against pathogenic diseases, such as hepatitis B [20] 
and influenza [21], and perhaps more impressively against antigen-expressing tumours [22], 
[23]. Initial gene delivery studies focused on applying DNA solutions to the skin, followed by 
application of solid microneedles [24], [25], however variability in dosing and high wastage 
of cargo have seen a shift towards the use of coated microneedles. Coating solid silicon or 
metal microneedles with rapidly dissolving DNA solutions enables a more consistent cargo 
loading and increased stability, however cargo delivery is limited to small quantities of DNA 
in the coating. Repeated drip-drying cycles may be used to increase the quantity of DNA 
present in coatings, however this is cumbersome and may affect needle conformation, and 
hence the ability to penetrate the SC [21], [26]. Dissolvable microneedles have the potential 
to overcome these issues and deliver larger quantities of DNA, as cargo may be distributed 
throughout the whole needle as opposed to the coating [27]. Once applied, these structures 
swell within the interstitial fluid in the skin and undergo rapid dissolution to release their 
payload, thus it is essential that the needles are composed of biocompatible material and 
possess sufficient strength in the dry state to penetrate the SC.  Importantly, novel fabrication 
processes for polymeric needles have been described to improve the scalability, and hence 
accessibility, of these devices [27], [28]. For example, Lutton et al (2015), reported on a 
novel scalable manufacturing process for hydrogel needles [28]. Using a combination of 
injection moulding and roller casting, the authors were able to fabricate highly reproducible 
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polymeric microneedles at ambient temperatures and low cost. Arrays possessed similar 
characteristics to microneedles produced using their previously reported centrifugation 
method, but avoided the labour intensive process [28]. Hence, the limitations of small scale 
batch manufacturing methods currently used for microneedle fabrication within the 
laboratory, such as the time-consuming nature and material wastage [29], are likely to be 
overcome when moving to production at an industrial scale using similar systems. 
Although dissolvable microneedles have been examined extensively as drug delivery tools 
there have only been a few reports of dissolvable microneedles being used for nucleic acid 
delivery in vivo [20], [29]–[31]. The stability of inactivated viruses and protein antigens has 
been established in certain dissolvable microneedle formulations [32]–[34] however, little 
investigation has been done to determine whether incorporation into dissolvable microneedles 
has any influence on the stability of DNA or to directly compare the suitability of different 
polymer matrices to deliver nucleic acid cargo. This is perhaps surprising given that some 
polymers have been known to form hydrogen bonds with DNA and have been reported to be 
capable of enhancing gene delivery in their own right [35]. Therefore the current study is 
designed to determine the optimal polymer for delivery of nucleic acid cargo. Four different 
polymers were used to form dissolvable microneedles, loaded with or without nucleic acid 
cargo. The effect of needle composition on mechanical properties, the ability to release DNA 
and the functional stability of the DNA following release from the polymer matrices is 
reported. In addition, the ability of a novel amphipathic peptide, RALA [36], to improve 
DNA recovery and transfection efficacies following release from polymer matrices is 
investigated. 
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2. Materials and Methods 
2.1 Materials 
2.1.1 RALA peptide 
The RALA peptide was purchased from Biomatik (USA) and supplied as an acetate salt in 
lyophilised form. The RALA peptide was stored at -20oC and reconstituted in DNase/RNase 
Free Water (Life Technologies, UK) immediately prior to use. 
2.1.2 Plasmids 
Reporter plasmids coding green fluorescent protein (GFP), pEGFP-N1, and luciferase, 
pCMV-Red Fire-fly Luc, were purchased from Clontech (USA) and Addgene (USA) 
respectively. Plasmids were transformed into and amplified in competent Escherichia coli 
DH5α cells (Life Technologies, UK). Prior to use plasmids were isolated and purified from 
transformed DH5α cells using PureLink HiPure Plasmid Filter Maxiprep Kits (Life 
Technologies, UK). DNA purity and concentration were determined according to UV 
absorbance at 260 and 280 nm (NanoDrop 2000c, Thermo Scientific, UK).  
2.1.3 Dissolvable Polymers 
Polyvinylpyrrolidone (PVP) with molecular weight 58,000 Da (PVP-58) and 360,000 Da 
(PVP-360) were purchased from Ashland Inc (USA) and Sigma Aldrich (UK) respectively. 
Polyvinyl alcohol (PVA) with molecular weight 13-23,000 Da (PVA-13-23) and 9-10,000 Da 
(PVA-9-10) were both purchased from Sigma Aldrich (UK). 
2.1.4 Cell Line and Cell Culture 
NCTC 929 murine fibroblast cells were purchased from American Type Culture Collection 
(USA) and maintained in Minimum Essential Media (MEM) (Life Technologies, UK) 
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supplemented with 10% Foetal Horse Serum (FHS) (Life Technologies, UK) at 37oC with 
5% CO2. Opti-MEM (Life Technologies, UK) was used for cell transfection protocols. 
2.1.5 Other Reagents 
MTS cell proliferation assay media, CellTiter 96 Aqueous One Solution Reagent, was 
purchased from Promega (USA). D-Luciferin was purchased from Gold Biotechnology 
(USA), Proteinase K and Tris(hydroxymethyl)aminomethane were purchased from Sigma 
Aldrich (UK). Primers for qRT-PCR were purchased from Integrated DNA Technologies 
(UK). Quanti-iT Picogreen Reagent was purchased from Life Technologies (UK). 
2.1.6 Animals 
Male C57 BL/6 mice, 6-8 weeks old, were purchased from Harlan UK Ltd (UK). Mice were 
housed in an open facility with unlimited access to food and water. All experimental 
procedures were carried out under project license 2794 and complied with the UK Scientific 
Act 1986. 
2.2 Preparation of RALA/DNA nanoparticles 
RALA/DNA nanoparticles were prepared at varying concentrations at the desired N:P ratio 
(the ratio of the positively charged nitrogen atoms from the peptide to the negatively charged 
phosphates on the DNA backbone) as described elsewhere [36]. Briefly, the RALA peptide 
solution was added to DNA solutions and nanoparticles were left to incubate for 30 min at 
room temperature prior to use. 
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2.3 Manufacture of dissolvable microneedle arrays 
Silicon microneedle moulds, prepared as described previously [37], were used as a template 
for microneedle formulation. Arrays consisted of 361 (19x19) conically shaped needles 
measuring 600 µm in length, with a base width of 300 µm and 50 µm spacing. 
To prepare cargo-free arrays approximately 500 mg of 20% w/w (PVP-360, PVA-13-23 and 
PVA-9-10) or 300 mg of 30% w/w (PVP-58) aqueous polymer solution was added to 
micromoulds, centrifuged for 10 min at 4,000 rpm and allowed to dry at room temperature 
for 48 h prior to use. Following 24 h of drying at room temperature 500 mg of PVP-360 was 
added to arrays fabricated from PVP-58 and centrifuged for 10 min at 4,000 rpm. 
To prepare RALA/pDNA loaded arrays, RALA/pDNA solutions were mixed at a ratio of 
60:40 with concentrated aqueous polymer stock solutions (50% w/w for PVP-360, PVA-13-
23 and PVA-9-10 and 75% w/w for PVP-58). To prevent wastage of DNA cargo, 25 mg of 
aqueous polymer-RALA/pDNA solutions were then added to the micromoulds and 
centrifuged for 10 mins at 4,000 rpm to fill the micromould indents. To form an inert 
supporting baseplate 500 mg of 20% w/w (PVP-360, PVA-13-23 and PVA-9-10) or 200 mg 
of 30% w/w (PVP-58) aqueous polymer solution was added to the moulds and centrifuged for 
10 min at 4,000 rpm. Following 24 h of drying at room temperature 500 mg of PVP-360 was 
added to arrays fabricated from PVP-58 and centrifuged for 10 min at 4,000 rpm. Arrays 
were then left to dry at room temperature for a further 24 h prior to use. 
Following drying, arrays were carefully peeled from moulds and sidewalls were removed 
with a heated scalpel immediately prior to use. 
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2.4 Visual Assessment of needle characteristics 
Prior to imaging, microneedle arrays were adhered to a flat steel block using double-sided 
tape and positioned perpendicular to the microscope. Arrays were imaged using at x35 
magnification using a Leica EZ4D digital microscope (Leica, Germany) and needle lengths 
were measured using inbuilt microscope software. 
2.5 Mechanical testing of microneedle arrays 
Mechanical properties of microneedles were assessed using a TA-XT2 Texture Analyser 
(Stable Microsystems, UK). Microneedle arrays were measured, adhered with double-sided 
tape to the movable probe of the TA-XT2 Texture Analyser and subjected to a compression 
force for 45 N (0.125 N/needle) for 30 s. Following compression, needles were re-measured 
and percentage height reduction was calculated as the difference in microneedle height 
following compression divided by the original height multiplied by 100. 
2.6 Microneedle array penetration into neonatal porcine skin 
Microneedle penetration into the skin was assessed using optical coherence tomography 
(OCT). Neonatal porcine skin was used as a model for penetration studies. Skin was stored at 
-20oC between experiments. Immediately prior to analysis skin was thawed in PBS at 37oC 
for 30 min and carefully shaved using a disposable razor. Skin was placed, SC side facing up, 
on to a sheet of dental wax for support and DNA free-microneedles were then inserted into 
the skin using manual pressure, and held in place for 30 s. Following insertion, images of 
needle penetration were obtained using an EX1301 OCT microscope (Michelson Diagnostics 
Ltd, UK). Image J software (National Institutes of Health, USA) was then used to analyse 2D 
images of microneedle penetration into skin. Accurate measurements of needle penetration 
depths were obtained using the scale of the images where 1.0 pixel = 4.2 µm, and percentage 
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penetration depth was assessed as needle length inserted into the skin divided by the total 
needle length multiplied by 100. The microneedle penetration volumes were subsequently 
determined using the equation V =π x r2 x (h/3), where r is the microneedle radius at the point 
of penetration, and h is the length of microneedle inserted into the skin. The percentage 
penetration volume was determined as the volume of needle inserted in the skin divided by 
the total needle volume multiplied by 100. 
2.7 Assessment of cell viability following exposure to polymers matrices 
The affect of exposure to polymer matrices was assessed using the MTS cell proliferation 
assay in the NCTC 929 fibroblast cell line. This cell line has been previously used to assess 
the biocompatibility of dissolvable microneedle formulations [29], and is listed by ATCC as 
being suitable for toxicity testing and transfection studies (www.lgcstandards-
atcc.org/products/all/CCL-1). NCTC 929 fibroblast cells were seeded into 96 well plates at 
densities of 10,000 cells/well and left to adhere overnight. The following day polymers were 
added to wells at concentrations of 0-40 mg/mL in complete media and cells were incubated 
for a further 24 h. After this time, media was removed and replaced with 200 µL/well of fresh 
complete media and supplemented with 10% CellTiter 96 Aqueous One Solution Reagent. 
Cells were incubated for a further 2 h at 37oC and 5% CO2 and the absorbance at 490 nm was 
subsequently measured using an EL808 96-well plate reader (BioTek Instruments Inc, UK). 
Control cells, not exposed to any polymer, were taken to be 100% viable and the cell viability 
of cells exposed to increasing concentrations of polymer was determined as a percentage of 
the absorbance of untreated control cells. 
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2.8 DNA Recovery and Integrity Analysis following incorporation into the dissolvable 
polymer matrices 
To avoid wastage of DNA and the time-consuming process of manufacturing microneedles, 
the effect of polymer matrices on DNA recovery, integrity and transfection efficacies was 
determined using polymer gels manufactured in silicon micromoulds lacking needle indents.  
For DNA recovery experiments 250 mg polymer gels containing 10 µg of pEGFP-N1 were 
prepared by mixing RALA/pEGFP-N1 solutions (N:P 0-10) at a ratio of 60:40 with 
concentrated aqueous polymer stock solutions (50% w/w for PVP-360, PVA-13-23 and PVA-
9-10 and 75% w/w for PVP-58). Following drying polymer gels were completely dissolved in 
TRIS buffer (pH 8) and samples were incubated with Proteinase K 1.0 mg/mL solution for 2 
h at 37oC to allow dissociation of pDNA from the RALA peptide prior to analysis. pDNA 
release was quantified using the Quanti-iT Picogreen Assay. 
For DNA integrity experiments polymer gels containing 30 µg of pEGFP-N1 (N:P 0 and 6) 
were fabricated as above. Following drying polymer gels were completely dissolved in TRIS 
buffer (pH 8) and samples were incubated in TRIS buffer (pH 8) with or without Proteinase 
K 1.0 mg/mL solution for 2 h at 37oC. Samples were then electrophoresed for 1 h on a 1% 
agarose gel incorporating Ethidium Bromide which was then imaged using the Multispectrum 
Bioimaging System (UVP, UK). 
2.9 In vitro transfection analysis following release from the polymer matrices 
For DNA transfection protocols polymer gels were prepared as above containing 20 µg of 
pEGFP-N1 (N:P 0-12) and left to dry at room temperature for 48 h. NCTC 929 fibroblast 
cells were seeded into 24 well plates at densities of 100,000 cells/well and left to adhere 
overnight. The following morning complete media was removed from wells and replaced 
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with 500 µL Opti-MEM reduced serum media for 2 h. Dried polymer gels were dissolved in 
1,000 µL of Opti-MEM media for 1 h and subsequently 250 µL/well samples were incubated 
with NCTC 929 cells for 6 h at 37oC and 5% CO2. Following this time the cell supernatant 
was removed and replaced with 500 µL of complete media. Cells were then incubated for a 
further 48 h at 37oC and 5% CO2 prior to analysis of transfection efficacy. 
To visualise GFP expression following transfection cells were imaged at x10 magnification 
using the EVOS FL Cell Imaging System (Thermofisher Scientific, UK). Following imaging 
cells were trysinised, harvested in 2% Formaldehyde and stored at 4oC prior to flow 
cytometric analysis. GFP expression was detected using the FACS Calibur System (BD 
Bioscience, UK) and the data was analysed using Cyflogic software (CyFlo Ltd, Finland). 
2.10 Quantification of DNA recovery and delivery from RALA/DNA loaded 
microneedles 
Dissolvable microneedle arrays were formulated with 32 µg of pDNA by dilution of 
concentrated polymer stock with RALA/pDNA (N:P 10) aqueous solution, as described 
previously. The quantity of DNA residing in the microneedle array following manufacture 
was determined using the Picogreen assay as previously described. Sidewalls were removed 
prior to experimentation to allow separate analysis from arrays (comprised of baseplate and 
microneedles). 
Following determination of RALA/pDNA loading within dissolvable microneedle patches, 
the quantity of pDNA delivered in vivo from arrays was determined. Dissolvable 
microneedles were formulated using 32 µg of pDNA complexed into RALA/pDNA (N:P 10) 
nanoparticles as above, and sidewalls were removed prior to experimentation. Female 
C57/BL6 mice were anaesthetised using 5% Isofluorane in an induction chamber Following 
induction, anaesthesia was maintained using 3% Isofluorane delivered via a face mask during 
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microneedle application.  Microneedle arrays were applied into the dorsal side of mouse ears 
using manual application, and held in place for 5 min with gentle pressure. Subsequently, 
arrays were held in place for a further 24 h using 3M surgical tape (Micropore Ltd, UK), 
prior to removal to allow quantification of pDNA remaining in the microneedle patch using 
the Picogreen assay. The quantity of pDNA delivered to mouse ears was calculated by 
subtracting the quantity of pDNA remaining in microneedle arrays following application to 
mouse ears from the quantity of pDNA in unapplied microneedle arrays. 
3. Results 
3.1 Microneedle formulation, characterisation and skin insertion studies 
Dissolvable microneedles were successfully formed by simple centrifugation of a range of 
aqueous polymer solutions (PVP-360, PVP-58, PVA-13-23 and PVA-9-10) into silicon 
micromoulds (Figure 1A). The baseplate of arrays formulated from PVP-58 cracked upon 
peeling from the mastermould, necessitating the addition of less brittle PVP-360 to form a 
secondary baseplate layer. To determine whether the polymer formulation significantly 
affected the mechanical strength of needles, arrays were subjected to a 45 N axial 
compression and reimaged to determine the percentage height reduction. No needle fracture 
was apparent following compression and in addition, needle conformation was largely 
unchanged (Figure 1B), although a slight blunting of the tip ends was observed. Needles 
composed of PVA-9-10 underwent the greatest reduction in height (10.237% ± 0.807), 
although this was not significantly higher than arrays composed of PVA-13-23, which 
resisted compression most effectively (7.077% ± 1.446, p > 0.05) (Figure 1C). 
The functional ability of the dissolvable microneedles to breach the SC was then next 
assessed using OCT. Arrays were applied into the SC facing side of neonatal porcine skin 
using manual pressure and immediately imaged. Cross-sectional images of microneedles 
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following application revealed a highly consistent, clear penetration through the SC (Figure 
1D) where needle penetration depths varied from 78.50% ± 0.956 (PVA-9-10) to 70.39% ± 
1.837 (PVP-58) (p > 0.05), corresponding to between 48.53% ± 2.79 (PVA-9-10) to 35.13% 
± 1.80 (PVP-58) (p < 0.05) of the total needle volume being inserted into the skin (Figure 
1E). 
3.2 Cytotoxicity Assays 
To investigate the potential toxicity of polymers to cells, NCTC-929 cells were exposed to 
dissolved DNA-loaded polymers and examined following 24 h for signs of stress or apoptosis 
(Figure 2a). Following exposure, cells maintained their conformation, showed no signs of 
shrinkage, membrane damage or blebbing, key morphological signs of apoptosis [38], 
indicating that exposure to polymer matrices did not result in cell damage. The effect of 
increasing concentrations of polymers (PVP-360, PVP-58, PVA-13-23 and PVA-9-10) on 
cell viability was then examined via MTS assay (Figure 2b). The viability of cells was not 
significantly affected by exposure to PVP-58, PVA-13-23 or PVA-9-10 for 24 h (p < 0.05) 
and did not drop below 80%, even at concentrations up to 40 mg/mL. Conversely, cell 
viability decreased with exposure to increasing concentrations of PVP-360, with 
concentrations of 20 mg/mL and 40 mg/mL causing a significant decrease in cell viability to 
below 80% (p < 0.05). 
3.3 DNA recovery and stability within polymer formulations 
To determine the quantity of pDNA that could be recovered from the respective polymer 
matrices polymer gels were formulated with known quantities of pDNA (10 µg) complexed 
to increasing amounts of RALA peptide. Polymer gels were then dissolved and the quantity 
of DNA released was determined via Picogreen assay. The quantity of pDNA recovered from 
PVA matrices was maximal across the range of N:P ratios examined (Figure 3A - iii and iv). 
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Conversely, at N:P 0 (naked pDNA) the quantity of pDNA recovered from PVP matrices was 
7.293 ± 1.240 µg and 7.741 ± 0.2119 µg from PVP-360 and PVP-58 respectively. pDNA 
recovery from PVP matrices increased with N:P ratio, up to N:P 4 when all of the loaded 
pDNA was recovered (Figure 3A - i and ii). 
Gel electrophoresis was subsequently used to assess the stability of pDNA following 
incorporation into polymer formulations, either alone or complexed to RALA (N:P 6). 
Following incorporation into PVP formulations there was a clear loss of pDNA stability as 
the DNA conformation changes from predominantly supercoiled to nicked (Figure 4B-i 
Lanes 3 and 4). In addition, pDNA bands appear indistinct and smeared on the gel, 
supporting that at lower N:P ratios pDNA recovery from PVP formulations was compromised 
by pDNA degradation. Naked pDNA released from PVA formulations also shows a change 
in pDNA tertiary structure, although a high proportion of the supercoiled conformation was 
retained and there is no evidence of DNA degradation (Figure 4B-i Lanes 5 and 6). Following 
incorporation into polymer matrices RALA/pDNA nanoparticles remain intact, as shown by 
the inability of DNA to run through the agarose gel (Figure 4B-i Lanes 11 - 14). This is 
because nanoparticles have an overall positive charge and so do not migrate through the 
agarose gel upon application of a current. Therefore, in order to visualise the pDNA 
conformation, nanoparticles were incubated with Proteinase K to digest the RALA peptide 
prior to analysis (Figure 4B-i Lanes 7 - 10). Complexing pDNA to RALA prior to 
incorporation into PVP formulations led to some preservation of the supercoiled 
conformation and protected pDNA from degradation within the matrix, although the majority 
of the pDNA remained in the nicked conformation (Figure 4B-i Lanes 7 and 8). Conversely, 
complexing pDNA into nanoparticles prior to incorporation into PVA formulations did not 
cause a significant change to pDNA stability (Figure 4B-i Lanes 9 and 10). These results 
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illustrate that RALA peptide is necessary to prevent DNA degradation within PVP matrices 
and that the pDNA stability is compromised upon drying within polymer formulations. 
Formulations were further incubated for 7 days at room temperature prior to investigate 
whether pDNA underwent further conformational changes following short-term storage. 
Further pDNA degradation is evident with naked pDNA released from PVP formulations 
(Figure 4B-ii Lanes 3 and 4), and a further loss of the supercoiled pDNA conformation is 
evident from naked pDNA released from PVA formulations (Figure 4B-ii Lanes 5 and 6). 
Complexing pDNA into nanoparticles led to a preservation of the pDNA structure with 
storage, as the proportions of pDNA in the supercoiled and nicked conformations remained 
largely unchanged after 7 days of storage (Figure 4B-ii Lanes 7 -10). 
3.4 In vitro transfection efficacy  
To assess whether pDNA remained functional following incorporation into polymer 
formulations, despite the change in structure, the transfection efficacy of pEGFP-N1 or 
RALA/pEGFP-N1 nanoparticles was determined in NCTC 929 cells following dissolution 
from loaded polymer gels. Cells incubated with naked pDNA demonstrated limited 
transfection following release from all polymers, however, as the quantity of RALA 
complexed to DNA (N:P ratio) increased, GFP expression due to transfection became more 
apparent (Figure 4A). Despite an increase in transfection efficacy, GFP expression following 
release of RALA/pEGFP-N1 nanoparticles from PVP-360 formulations remained limited 
throughout the range of N:P ratios (Figure 4A-i). Quantitative analysis of GFP transfection 
efficacies via flow cytometry was reflective of fluorescent images, demonstrating 
significantly higher transfection efficacies were achieved with increasing N:P ratio compared 
to naked DNA (Figure 4B). The highest transfection efficacy achieved was 43.69% ± 4.598, 
following cell incubation with RALA/pEGFP-N1 nanoparticles (N:P 12) recovered from 
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PVA-13-23 matrices. Similar transfection rates were seen following incubation with 
nanoparticles (N:P 12) released from PVA-9-10 formulations (43.35% ± 0.9778) (p > 0.05), 
however significantly lower transfection efficacies were achieved following release of 
nanoparticles (N:P 12) from PVP-360 (p=0.0019) and PVP-58 (p=0.0340) formulations. 
These results demonstrate that the functional integrity of pDNA has been compromised by 
incubation within PVP formulations. This loss of transfection efficacy may be related to the 
loss of DNA supercoiled conformation, which is greater within PVP formulations (Figure 
3B). 
3.5 Formulation and mechanical testing of DNA loaded microneedles 
pDNA-loaded microneedles were formulated by centrifugation of aqueous polymer, diluted 
with pDNA or RALA/pDNA nanoparticle solution, to form needle tips prior to addition of an 
inert baseplate layer. To minimise the possibility of microneedle mechanical failure the 
concentration of polymer solution used for formulation remained consistent (20% PVP-360, 
PVA-13-23 and PVA-9-10, and 30% w/w for PVP-58). The quantity of pDNA that could be 
loaded into microneedle arrays was therefore limited by the workable concentrations of 
pDNA and RALA peptide which could be used for dilution of concentrated polymer stock. 
The concentrations of pDNA and RALA solutions used for microneedle formulation were 7.5 
µg/mL and 43.5 µg/mL respectively. RALA/pDNA solutions at N:P 10 were chosen for 
mechanical strength comparisons which allowed a hypothetical pDNA loading of 32 µg per 
array (Figure 5A-i). 
Arrays loaded with pDNA or RALA/pDNA nanoparticles were subjected to an axial 
compression force of 45 N and the needle percentage height reduction was calculated as 
previously described. Similarly to unloaded arrays, needles showed a blunting of tip ends 
(Figure 5A-ii) but underwent no major deformation or buckling. Incorporation of pDNA or 
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nanoparticle cargo into arrays did not compromise needle mechanical properties, and none of 
the needles tested underwent a height reduction greater than 10% of the original needle length 
(Figure 5B). Therefore it was concluded that pDNA loaded needles would be able to disrupt 
the SC in a similar manner to unloaded microneedle arrays. 
3.6 DNA recovery and delivery from loaded microneedle arrays 
As it is likely that some pDNA shall be lost during the manufacturing process, the DNA 
loading in the baseplate and microneedles of arrays, was determined using the Picogreen 
assay. Microneedle arrays (baseplate and needles) composed of 20% w/w 9-10 kDa PVA 
were found to release the highest quantity of pDNA (17.7 µg), which was significantly 
greater than quantities of pDNA released from arrays composed of 360 kDa PVP (12.6 µg, p 
< 0.001), 58 kDa PVP (14.2 µg, p < 0.01) and 13-23 kDa PVA (15.4 µg, p < 0.05) as 
determined by one-way ANOVA (Figure 6A). 
It was found that a large portion of pDNA was lost into the sidewalls for all microneedle 
formulations (Figure 6B), with 14.3 µg, 12.3 µg, 13.2 µg and 14.4 µg of pDNA being 
recovered from the sidewalls of 360 kDa PVP, 58 kDa PVP, 13-23 kDa PVA and 9-10 kDa 
PVA formulations respectively. 
Following determination of the quantity of pDNA encapsulated into the baseplate and needles 
of microneedle arrays, the quantity of pDNA actually delivered from the patches in vivo was 
determined. Loaded microneedle arrays were applied to the dorsal side of mouse ears for 24 h 
and the pDNA remaining in the microneedle arrays following removal from mouse ears was 
determined. The quantity of pDNA delivered into mouse ears in vivo was subsequently 
estimated by subtracting the quantity of pDNA remaining from the pDNA loaded into the 
microneedle array prior to application (Figure 6C). The greatest quantity of pDNA delivered 
in vivo was 12.5 µg (17.7 μg - 5.2 µg) from the 9-10 kDa PVA formulations, although not 
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significantly greater than the quantity of pDNA delivered from 360 kDa PVP (9.6 µg), 58 
kDa PVP (10.9 µg) or 13-23 kDa PVA (8.6 µg) microneedle arrays. 
4. Discussion 
Recently, we reported on the development of a novel dissolvable 360 kDa PVP microneedle 
system incorporating cationic RALA/pDNA nanoparticles to aid transfection [29]. Although 
the recovered pDNA cargo was capable of eliciting gene expression in vitro and in vivo, 
transfection efficiency was reduced compared to fresh nanoparticles [36], indicating a loss of 
functionality. Given that PVP has previously been reported to form hydrogen bonds with 
DNA, this loss in transfection efficacy was not entirely unexpected [26]. This then prompted 
us in this study to examine the suitability of four FDA-approved polymer formulations to 
form dissolvable microneedles for DNA vaccination. In addition, we incorporated the 
amphipathic cationic peptide RALA prior to formulation to enhance the functionality of the 
DNA cargo.  
Firstly, it was established that all chosen formulations (PVP-360; PVP-58; PVA-13-23 and 
PVA-9-10) were equally suitable for microneedle fabrication. As with our previous study, we 
fabricated microneedles with 600 μm length in order to target DNA delivery to the epidermal 
and dermal layers of the skin. Previous work has demonstrated that utilising this needle 
length results in microneedle penetration depths of 400-500 μm in pig skin, with no 
significant benefit observed with increasing needle length to 900 μm (penetration depths of 
500-600 μm in the same model) [39]. As the human epidermis differs in thickness from ~70-
180 μm this needle length is expected to fully penetrate through this layer into the upper 
layers of the dermis [40], [19]. Therefore dissolution of the microneedle structure shall allow 
cargo to be targeted to both epidermal LCs and dermal DCs across a range of application sites 
[13]–[15]. Previous studies have reported that a lesser strength is one of the limitations of 
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dissolvable microneedle matrices compared solid microneedles which can adversely affect 
penetration of the SC. Larrañeta et al (2014) determined that volunteers use a maximum 
average insertion force of 32 N when applying dissolvable microneedle patches [39]. In the 
above experiment 2 volunteers (of 20) were found to exert an average exertion force of ~40 N 
when applying microneedles [39], and therefore 45 N was selected as the application 
forcearrays must be capable of withstanding without significant deformation. Following a 45 
N compression force, there was no significant difference in needle height reduction indicating 
that the formulations should have sufficient strength to withstand insertion (Figure 1). 
Penetration of the SC is another critical factor to consider with dissolving microneedles and 
this is related to needle sharpness and strength of the formulating polymer [19], [27], [41]. 
Therefore the ability of microneedles to penetrate the SC was subsequently tested using 
neonatal porcine skin as a model for human skin. Penetration depths achieved in this study 
were approximately 70-80% of the needle length across the range of polymers tested (Figure 
1), which is similar to or greater than the penetration depths achieved using solid or coated 
needles [26], [30], [42]. Therefore we could be confident that a large proportion of the 
payload within the dissolvable polymer matrix would be deposited into the skin following 
microneedle insertion. The microneedle type can affect the outcomes of incomplete insertion. 
For example, coated microneedles will only deliver the cargo present on the inserted part of 
the needle [26]. In contrast, incomplete insertion of dissolvable needles may not be as 
limiting as dissolution of needles creates transient pores in the SC facilitating the passage of 
cargo from the un-inserted needle portion and the baseplate. This can be further enhanced 
when the interstitial fluid is absorbed and spreads through the polymer matrix during the 
dissolution process [43]. Given that all formulations in this study produced strong, sharp 
microneedles all four polymers displayed suitable characteristics for further in vitro analysis.  
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Given that the dissolvable matrix as well the cargo is deposited into the skin, the choice of 
polymer is also a critical factor. PVP has been shown to be almost completely eliminated 
through the kidneys at lower molecular weights < 25 kDa, which is approximately the limit 
of glomerular filtration in rat kidneys [44]. However, as the molecular weight of PVP 
increases, elimination is reduced and the PVP is retained in the reticulo-endothelial system 
[45], [46], and injection of PVP with molecular weight > 100 kDa has been shown to lead to 
storage disease [47].  As such, the high molecular weight of PVP-360, used by McCaffrey et 
al (2016) for microneedle fabrication,[29] may render it unsuitable for patient administration. 
Similarly, PVA elimination rates depend largely on the injection site and the molecular 
weight of the polymer, with the cut off size for glomerular filtration being 30 kDa [48]. 
Studies examining the fate of larger molecular weights of PVA have shown accumulation 
within the liver and spleen of rats [49]. From these collective studies it is clear that the 
molecular weight of the polymer should be as low as possible to ensure complete elimination. 
To date most studies have focused on intravenous administration of polymers and therefore in 
order license a dissolvable microneedle product further investigation into the distribution and 
elimination following repeated intradermal (i.d.) administration will be crucial. Should the 
formulating polymer be retained in the skin for any period it is critical that no loss of skin 
integrity should occur. Currently no guidance has been provided from regulators with regards 
the safety and toxicity standards which microneedles shall need to meet for licensure; 
however, the MTT and MTS viability assays, which measure cells’ mitochondrial metabolic 
rate, have been used previously to determine the biocompatibility of dissolvable microneedle 
formulations [29], [50]. Therefore we also examined the effect of increasing concentrations 
of polymer on cell viability in NCTC 929 fibroblast cells using the MTS viability assay. 
Results demonstrated that at concentrations up to 10 mg/mL, none of the polymers caused a 
significant decrease in cell viability. McCrudden et al (2014) found that exposure of L-132 
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cells to 5 mg/mL of MN formulation (PMVE/MA) resulted in greater than a 90% drop in cell 
viability yet this did not translate to significant loss of skin viability in a 3D model or 
irritation to rat skin in vivo following 24 h exposure to the MN formulation [50]. As such 
although higher concentrations of PVP-360 (20 mg/mL and 40 mg/mL) did result in a drop in 
cell viability below 80%, these concentration ranges are much higher than would be used in 
vivo, and are unlikely to result in damage to healthy skin.  
At this point all four polymers were considered suitable to proceed with, however further 
studies revealed that pDNA release from the PVP polymer matrices was compromised. In this 
case we were able to achieve complete recovery of pDNA from PVA matrices, and from PVP 
matrices where pDNA was complexed with RALA peptide at N:P ratios >4 (Figure 3). 
Quantification of pDNA release from polymer matrices is essential but gives little indication 
as to the integrity of the pDNA and further analysis by agarose gel revealed that pDNA was 
degraded within the PVP matrices. This loss of DNA integrity was not observed by Qiu et al 
(2015) within their dissolvable microneedle system, where pDNA functionality was 
determined via protein quantification following transfection with recovered pDNA [51]. One 
key difference may be that the solutions used for microneedle formulation in our study were a 
much higher concentration than those used by Qiu et al  (2015) (5% w/w 10 kDa PVP) and 
thus the effect on pDNA stability may be more apparent [51]. Degradation of naked pDNA 
was greater in the more highly concentrated 58 kDa PVP matrix (30% w/w) than the 360 kDa 
PVP matrix (20% w/w) (Figure 3). PVP has been previously reported to cause cleavage of 
DNA by hydrolysis of guanine and adenine bases [52]. During the formulation process it was 
observed that pDNA incorporated into PVA and PVP matrices also underwent a change in 
structure. To achieve high transfection efficacies retaining the supercoiled conformation of 
pDNA is desirable [53]. Therefore condensing agents such as PEI and Lipofectamine have 
been used to protect the pDNA during fabrication of polymer loaded films [54]. Here, 
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complexation with RALA peptide was able to protect pDNA from degradation within the 
PVP formulations, but unable to conserve the conformation during the formulation process 
(figure 3). Similar issues with pDNA integrity within coated and dissolvable matrices have 
been observed previously, although in some cases it has been reported that a loss of pDNA 
conformation is not necessarily an indicator of biological function [13,18].  
Indeed transfection studies revealed that the conformational changes in pDNA did not have a 
detrimental effect on gene expression following release from PVA matrices (Figure 4). 
RALA was able to significantly enhance gene expression in vitro approximately 10 fold and 
thus compensated for a restricted loading capacity within microneedles. Transfection 
efficacies of pDNA released from PVP matrices were lower, which could be explained by the 
loss of the supercoiled DNA conformation which was more apparent in PVP matrices, and in 
particular the PVP-360 formulation, where virtually none of the supercoiled conformation 
was retained. These transfection rates following release from PVP matrices were similar to 
those reported by McCaffrey et al (2016) where the transfection efficacy of RALA/pEGFP-
N1 (N:P 10) nanoparticles following release from 360 kDa PVP matrices was ~13% in the 
NCTC 929 cell line [29]. Incorporation of RALA/pEGFP-N1 nanoparticles into PVA 
matrices improved transfection efficacies to ~40% at the same N:P ratio (N:P 10). These 
studies demonstrate a clear rationale for the inclusion of delivery vectors such as RALA in 
microneedle-assisted DNA delivery systems. Of note is that freshly prepared RALA/pEGFP-
N1 nanoparticles (N:P 10) have previously been demonstrated to possess transfection rates as 
high as 60% in the same cell line [36], indicating that the formulation process could be 
further optimised to improve pDNA stability within the dissolvable matrix. Similar issues 
with pDNA integrity within coated and dissolvable matrices have been observed previously 
[13, 18] and so the addition of  stabilisers may be necessary to further conserve pDNA 
integrity.  
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Further to these studies it was necessary to determine how much cargo could be incorporated 
into the dissolvable microneedle arrays. Dissolvable microneedle systems have a limited 
carrying capacity as the incorporation of large amounts of cargo results in decreased 
mechanical needle properties [55]. In order to circumvent this issue the concentration of 
polymer solution used to create cargo-microneedles was kept constant (20% or 30% w/w) by 
diluting highly concentrated polymer stocks with RALA/pDNA solutions prior to 
microneedle fabrication. RALA/pDNA loaded microneedle retained sharpness and did not 
lose any of their mechanical robustness. In fact loading of pDNA or RALA/pDNA into the 
needles actually reduced deformation. This trend was also found by McCaffrey et al (2016) 
who noted that incorporation of pDNA or RALA/pDNA into PVP microneedle tips did not 
result in any significant difference to microneedle strength [22]. As such, pDNA loaded and 
RALA/pDNA loaded needles were considered suitable for in vivo applications. 
When scaling up for in vivo experiments a large portion of the cargo should be present in the 
tips and baseplate of microneedles, and should not be lost during the fabrication process. 
Therefore, following fabrication of RALA/pDNA loaded microneedle arrays the amount of 
pDNA residing in the baseplate and needles of arrays was quantified separately from the 
microneedle sidewalls. The quantity of pDNA present in the baseplate and microneedles 
varied from 39.4% to 55.0% of the loaded pDNA quantity, and as much as 45% of the pDNA 
payload was lost to the microneedle sidewalls. Additionally, up to 17% of the pDNA load 
was not recovered from formulation sidewalls or arrays, indicating a loss of pDNA cargo 
during the manufacturing process. These limitations could be overcome if microneedles were 
produced in a large-scale process which localised pDNA only to the tips and baseplate of 
dissolvable arrays. For example, McGrath et al (2014) described a novel atomised spray 
process to fabricate dissolvable microneedle arrays from multiple polymer and sugar 
formulations and were able to restrict the cargo exclusively to the microneedle tips [27].  
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Quantifying the amount of pDNA that could be delivered in vivo was determined via 
application of RALA/pDNA-loaded microneedle arrays to mouse ears for 24 h. Using this 
formulation we were able to load and deliver larger quantities of pDNA than other 
dissolvable devices previously reported, without compromising mechanical integrity [34, 35, 
52, 53]. Of our formulations, 9-10 kDa PVA microneedle arrays were found to contain 
significantly higher amounts of pDNA in the baseplate and needles than 360 kDa PVP, 58 
kDa PVP, and 13-23 kDa microneedle arrays, and subsequently delivered the greatest 
quantity of pDNA in vivo. Therefore the evidence from this study indicates that 9-10kDa 
PVA was the optimal polymer for fabrication of RALA/pDNA-loaded microneedle arrays.  
In conclusion this report highlights the importance of careful selection and thorough 
investigation of the dissolvable microneedle matrix prior to in vivo use, as polymer choice 
has a significant impact on cargo integrity and loading. These parameters will subsequently 
impact upon device functionality particularly for vaccine applications where both quantity 
and integrity of DNA will be critical to generate a potent immune response.  
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Figure 1. Dissolvable microneedle arrays produced by simple centrifugation are able to 
withstand high compression forces and penetrate the stratum corneum. (A) Light 
microscope images of microneedles formulated from i) 360 kDa PVP, ii) 58 kDa PVP, iii) 
13-23 kDa PVA and iv) 9-10 kDa PVA prior to and (B) following 45 N axial compression; 
(C) Percentage height reduction of needles following 45 N compression (means + SEM, 
N=3); (D) Optical Coherence Tomography (OCT) images of i) 360 kDa PVP, ii) 58 kDa 
PVP, iii) 13-23 kDa PVA and iv) 9-10 kDa PVA microneedle penetration into neonatal 
porcine skin following application of manual pressure and (E) the corresponding percentage 
penetration of arrays through the stratum corneum (means + SEM, N=3).  
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Figure 2. Effect of polymer formulation on NCTC 929 cell viability. (A) Digital 
microscope of images of NCTC 929 fibroblast cells 24 h following exposure to dissolved 
DNA loaded i ) 360 kDa PVP, ii) 58 kDa PVP, iii) 13-23 kDa PVA and iv) 9-10 kDa PVA 
polymer matrices; (B) Cell viability of NCTC 929 cells following 24 h exposure to increasing 
concentrations of i ) 360 kDa PVP, ii) 58 kDa PVP, iii) 13-23 kDa PVA and iv) 9-10 kDa 
PVA polymer, expressed as percentage viability compared to untreated control (means + 
SEM, n=3).  
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Figure 3. The effect of polymer matrices on DNA recovery and integrity. (A) Recovery 
of DNA following incorporation into i) 360 kDa PVP, ii) 58 kDa PVP, iii) 13-23 kDa PVA 
and iv) 9-10 kDa PVA polymer gels at various N:P ratios (N:P 0-10) (mean + SEM, n=3); 
(B) Gel electrophoresis of DNA (N:P 0) and RALA/DNA nanoparticles (N:P 6) following 
dissolution from polymer matrices following storage at room temperature for i) 0 or ii) 7 
days. Lane 1: 1 kB DNA ladder, Lane 2: control DNA Lanes 3 - 6: DNA (N:P 0) recovered 
from 360 kDa PVP, 58 kDa PVP, 13-23 kDa PVA and 9-10 kDa PVA polymer gels 
incubated with Proteinase K, Lanes 7 – 10: RALA/DNA nanoparticles (N:P 6) recovered 
from 360 kDa PVP, 58 kDa PVP, 13-23 kDa PVA and 9-10 kDa PVA polymer gels 
incubated with Proteinase K, Lanes 11 – 14: RALA/DNA nanoparticles (N:P 6) recovered 
from 360 kDa PVP, 58 kDa PVP, 13-23 kDa PVA and 9-10 kDa PVA polymer gels 
incubated with TRIS buffer.  
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Figure 4. In vitro transfection efficacies of RALA/DNA nanoparticles at various N:P 
ratios (N:P 0-12) following dissolution from polymer matrices. (A) Representative 
fluorescent images and (B) cell transfection efficacies of NCTC 929 fibroblast cells following 
transfection with RALA/pEGFP-N1 nanoparticles released from i) 360 kDa PVP, ii) 58 kDa 
PVP, iii) 13-23 kDa PVA and iv) 9-10 kDa PVA polymer gels at various N:P ratios (N:P 0-
12), (mean + SEM, n=3).  
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Figure 5. Characterisation of dissolvable microneedle arrays loaded with DNA (N:P 0) 
and RALA/DNA nanoparticles (N:P 10). (A) Digital microscope images of microneedles 
formulated from i) 360 kDa PVP, ii) 58 kDa PVP, iii) 13-23 kDa PVA and iv) 9-10 kDa PVA  
loaded with RALA/DNA nanoparticles (N:P 10) prior to and (B) following 45 N axial 
compression; (C) Percentage height reduction of i) 360 kDa PVP, ii) 58 kDa PVP, iii) 13-23 
kDa PVA and iv) 9-10 kDa PVA arrays, unloaded or  loaded with DNA  only(N:P 0) or 
RALA/DNA nanoparticles (N:P 10) following 45 N compression (means + SEM, N=3).  
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Figure 6. Determination of RALA/pDNA delivery from loaded dissolvable microneedle 
arrays in vivo (A) Quantification of RALA/DNA encapsulation within the microneedle array 
baseplate and needles following drying and sidewall removal (B) Quantification of 
RALA/DNA encapsulation within removed microneedle sidewalls(C) Quantification of 
RALA/DNA delivered from loaded microneedle arrays in vivo following application to 
mouse ears for 24 h.  
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